Will a once-weekly anticoagulant for the treatment and secondary prevention of thromboembolism improve adherence?

Thrombosis and Haemostasis

Volumn 101, Issue 3, 2009, Pages 422-427

  Cohen, Alexander T ^a   Maillardet, Louise ^a   Yavin, Yshai ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Adherence; Anticoagulant; Dose frequency; Idraparinux; Thromboembolism

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTIOXIDANT; ANTIVITAMIN K; APIXABAN; BETA1A INTERFERON; BISPHOSPHONIC ACID DERIVATIVE; DABIGATRAN ETEXILATE; DU 176B; FLUOXETINE; HEPARIN; IDRAPARINUX; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; NICOTINIC ACID; PLACEBO; PROTEIN C; RAZAXABAN; RECOMBINANT THROMBOMODULIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN; YM 150;

ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DEPRESSION; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; FOOD; FOOD DRUG INTERACTION; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MAJOR DEPRESSION; MENINGOCOCCEMIA; MULTIPLE SCLEROSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; SECONDARY PREVENTION; SEPSIS; STROKE; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FOOD-DRUG INTERACTIONS; HALF-LIFE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MEDICATION ADHERENCE; OLIGOSACCHARIDES; SECONDARY PREVENTION; THROMBOEMBOLISM; WARFARIN;

EID: 62549104877     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-02-0094     Document Type: Article

References (49)

1. Ansell J, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl): 204S-233S.
2. Jones M, et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 2005; 91: 472-477.
3. De Schry ver EL, et al; Dutch TIA trial and SPIRIT study groups. Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischaemic stroke. J Neurol 2005; 252: 1316-1321.
4. Budnitz DS, et al. National surveillance of emergency department visits for outpatient adverse drug events. J Am Med Assoc 2006; 296: 1858-1866.
5. U.S. Food and Drug Administration. 2006 Safety-alerts for drugs, biologics, medical devices, and dietary supplements. October 6, 2006. Available at: http://www.fda.gov/medwatch/safety/2006/safety06.htm#Coumadin. Accessed February 12, 2008.
6. Wahl C, et al. Concordance, compliance and adherence in healthcare: closing gaps and improving outcomes. Healthe Q 2005; 8: 65-70.
7. Jackevicius CA, et al. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. J Am Med Assoc 2002; 288: 462-467.
8. Dunbar-Jacob J, et al. Adherence in chronic disease. Annu Rev Nurs Res 2000; 18: 48-90.
9. Arnsten JH, et al. Determinants of compliance with anticoagulation: A case-control study. Am J Med 1997; 103: 11-17.
10. Ingelgård A, et al. What are the barriers to warfarin use in atrial fibrillation?: Development of a questionnaire. J Thromb Thrombolysis 2006; 21: 257-265.
11. Osterberg L, Blasehke T. Adherence to medication. N Engl J Med 2005; 353: 487-497.
12. Palareti G, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-128.
13. de Vicente Cámara MP, et al. Major thromboembolic complications during oral anticoagulant therapy. Importance of level of anticoagulation. Sangre (Barc) 1999; 44: 469-172.
14. Wittkowsky AK, Devine EB. Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin. Pharmacotherapy 2004; 24: 1311-1316.
15. Geerts WH, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3 Suppl): 338S-400S.
16. Thom T, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113: e85-151.
17. Mackay J, Mensah GA. The Atlas of Heart Disease and Stroke. World Health Organization; 2004. Available at: http://www.who.int/cardiovascular-diseases/ resources/atlas/en/Accessed February 12, 2008.
18. Hansson PO, et al. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000; 160: 769-774.
19. Kumar S, et al. Effect of warfarin on plasma concentrations of vitamin K dependent coagulation factors in patients with stable control and monitored compliance. Br J Haematol 1990; 74: 82-85.
20. Van Gelder IC, et al; Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-1840.
21. Wyse DG, et al.; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
22. Waterman AD, et al. Effect of warfarin nonadherence on control of the International Normalized Ratio. Am J Health Syst Pharm 2004; 61: 1258-1264.
23. Brigden ML, et al. Audit of the frequency and clinical response to excessive oral anticoagulation in an outpatient population. Am J Hematol 1998; 59: 22-27.
24. Kumar S, et al. Poor compliance is a major factor in unstable outpatient control of anticoagulant therapy. Thromb Haemost 1989; 62: 729-732.
25. Hixson-Wallace JA, et al. Effect of regimen complexity on patient satisfaction and compliance with warfarin therapy. Clin Appl Thromb Hemost 2001; 7: 33-37.
26. Parker CS, et al. Adherence to warfarin assessed by electronic pill caps, clinician assessment, and patient reports: results from the IN-RANGE study. J Gen Intern Med 2007; 22: 1254-1259.
27. Nichol MB, et al. Quality of anticoagulation monitoring in nonvalvular atrial fibrillation patients: comparison of anticoagulation clinic versus usual care. Ann Pharmacother 2008 ; 42: 62-70.
28. Holbrook AM, et al. Systematic overview of warfarin and its drag and food interactions. Arch Intern Med 2005; 165: 1095-1106.
29. Fischer RG. Compliance-oriented prescribing: simplifying drug regimens. J Fam Pract 1980; 10: 427-435.
30. Bloom BS. Daily regimen and compliance with treatment. Br Med J 2001; 323: 647.
31. Cramer JA, et al. How often is medication taken as prescribed? A novel assessment technique. J Am Med Assoc 1989; 261: 3273-3277.
32. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984; 6: 592-599.
33. Claxton AJ, et al. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-1310.
34. Richter A, et al. The impact of reducing dose frequency on health outcomes. Clin Ther 2003; 25: 2307-2335.
35. Pettinger MB, et al. Compliance to multiple interventions in a high risk population. Ann Epidemiol 1999; 9: 408-418.
36. Orensky IA, Holdford DA. Predictors of noncompliance with warfarin therapy in an outpatient anticoagulation clinic. Pharmacotherapy 2005; 25: 1801-1808.
37. Wells PS, et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection. Arch Intern Med 1998; 158: 1809-1812.
38. Cramer JA, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005; 21: 1453-1460.
39. Van Staa TP, et al. Persistence to bisphosphonate treatment in actual clinical practice. Bone 2005; 36: 610.
40. Recker RR, et al. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005; 80: 856-861.
41. Weiss M, et al. Treatment preference and tolerability with alendronate once weekly over a 3-month period: an Israeli multi-center study. Aging Clin Exp Res 2005; 17: 143-149.
42. Claxton A, et al. Patient compliance to a new enteric-coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder. J Clin Psychiatry 2000; 61: 928-932.
43. Devonshire V et al.; on behalf of the GAP Study Group. The Global Adherence Project - A multicentre observational study on adherence to disease-modifying therapies in patients suffering from relapsing-remitting multiple sclerosis. Presentation at the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, September 27-30, 2006; Madrid, Spain.
44. Jahng KH, et al. Preferences for medical collaboration: patient-physician congruence and patient outcomes. Patient Educ Couns 2005; 57: 308-314.
45. Gage BF, et al. Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke 1998; 29: 1083-1091.
46. Herbert JM, et al. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998; 91: 4197-4205.
47. PERSIST investigators. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. J Thromb Haemost 2004; 2:47-53.
48. van Gogh Investigators, et al. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007; 357: 1094-1104.
49. van Gogh Investigators, et al. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 2007; 357: 1105-1112.